open access
A massive gross haematuria in an 85-year-old patient with acquired haemophilia A
Affiliations- Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland
- Department of Pathophysiology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz
- Department of Toxicology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz of Nicolaus Copernicus University in Toruń, Jurasza 2, 85-094 Bydgoszcz, Poland
- Department of Neurology, L. Perzyna Regional Unified Hospital in Kalisz, Poznańska 79, 62-800 Kalisz, Poland
open access
Abstract
The authors herein present a case report of an 85-year-old female patient with massive gross haematuria in the course of acquired haemophilia A. Acquired haemophilia in the geriatric population is a rare but severe bleeding disorder. It is caused by suddenly appearing autoantibodies that interfere with coagulation factor VIII activity. The diagnosis of acquired haemophilia should be considered in any patient who presents with bleeding and a prolonged activated partial thromboplastin time (APTT).
Abstract
The authors herein present a case report of an 85-year-old female patient with massive gross haematuria in the course of acquired haemophilia A. Acquired haemophilia in the geriatric population is a rare but severe bleeding disorder. It is caused by suddenly appearing autoantibodies that interfere with coagulation factor VIII activity. The diagnosis of acquired haemophilia should be considered in any patient who presents with bleeding and a prolonged activated partial thromboplastin time (APTT).
Keywords
haematuria, haemophilia, acquired haemophilia
About this articleTitle
A massive gross haematuria in an 85-year-old patient with acquired haemophilia A
Journal
Issue
Article type
Case report
Pages
178-180
Published online
2018-03-30
Page views
959
Article views/downloads
639
DOI
Bibliographic record
Medical Research Journal 2017;2(4):178-180.
Keywords
haematuria
haemophilia
acquired haemophilia
Authors
Katarzyna Mądra-Gackowska
Sylwia Ziółkowska
Marcin Gackowski
Emilia Główczewska-Siedlecka
Joanna Książak
Barbara Kaźmierczak
Kornelia Kędziora-Kornatowska
References (7)- Fischer K, Hermans C. European Haemophilia Therapy Standardisation Board. The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia. 2013; 19(1): 35–43.
- Narodowy Program Leczenia Chorych na Hemofilię i Pokrewne Skazy Krwotoczne na lata 2012-2018. Minister Zdrowia, Warszawa 2013. . www.mz.gov.pl/zdrowie-i-profilaktyka/krwiodawstwo/program-zdrowotny-narodowy-program-leczenia-chorych-na-hemofilie-i-pokrewne-skazy-krwotoczne-na-lata-2012-2018/.
- Charakterystyka Produktu Leczniczego Pradaxa 110/150 mg. http://leki.urpl.gov.pl/files/25_PRADAXA_kap_tw.pdf.
- Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010; 85(3): 185–187.
- Hosier GW, Mason RJ, Sue Robinson K, et al. Acquired hemophilia A: A rare cause of gross hematuria. Can Urol Assoc J. 2015; 9(11-12): E905–E907.
- Duran-Suarez JR. Incidence of circulating anticoagulants in a normal population. Acta Haematol. 1982; 67(3): 217–219.
- Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981; 45(3): 200–203.